SGLT2抑制剂在70岁以上2型糖尿病英国人群中的安全性与有效性:工具变量法研究
本研究利用英国初级保健数据(2013-2020),采用工具变量法比较SGLT2抑制剂与DPP4抑制剂在70岁以上及70岁以下2型糖尿病患者中的安全性和有效性。结果显示,70岁以上患者使用SGLT2抑制剂糖尿病酮症酸中毒风险增加(发生率比3.82),但发生率低;两组生殖器感染风险均增加;70岁以上患者HbA1c降幅与DPP4抑制剂相似,而70岁以下患者SGLT2抑制剂更有效。
要点
- 70岁以上患者使用SGLT2抑制剂糖尿病酮症酸中毒发生率比为3.82,但发生率低(29.6/万人年)。
- 两个年龄组使用SGLT2抑制剂生殖器感染风险均增加,发生率比分别为2.27和2.16。
- 70岁以上患者SGLT2抑制剂与DPP4抑制剂HbA1c降幅相似,而70岁以下患者SGLT2抑制剂更有效。
核心结论
- 因果分析提示SGLT2抑制剂在70岁及以上成人中有效,但增加生殖器感染和糖尿病酮症酸中毒风险。
- 本研究将随机对照试验证据扩展至老年2型糖尿病患者。
研究设计与样本
- 使用医院链接的英国初级保健数据(临床实践研究数据链,2013-2020),比较启动SGLT2抑制剂与DPP4抑制剂的个体不良事件和有效性。
- 分析按年龄分层:<70岁(SGLT2抑制剂n=66,810,DPP4抑制剂n=76,172),≥70岁(SGLT2抑制剂n=10,419,DPP4抑制剂n=33,434)。
- 采用工具变量因果推断方法,以处方者偏好作为工具变量。
主要发现
- ≥70岁患者使用SGLT2抑制剂糖尿病酮症酸中毒风险增加(与DPP4抑制剂相比发生率比3.82 [95% CI 1.12, 13.03]),<70岁患者未见增加(1.12 [0.41, 3.04])。
- ≥70岁患者使用SGLT2抑制剂糖尿病酮症酸中毒发生率低(29.6 [29.5, 29.7])/万人年。
- 两个年龄组SGLT2抑制剂均与生殖器感染风险增加相关(<70岁发生率比2.27 [2.03, 2.53];≥70岁2.16 [1.77, 2.63])。
- 两个年龄组使用SGLT2抑制剂均无证据显示血容量不足、排尿控制不佳、尿频、跌倒或截肢风险增加。
- ≥70岁患者SGLT2抑制剂与DPP4抑制剂HbA1c降幅相似(-0.3 mmol/mol [-1.6, 1.1],-0.02% [0.1, 0.1]),<70岁患者SGLT2抑制剂更有效(-4 mmol/mol [4.8, -3.1],-0.4% [-0.4, -0.3])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis. METHODS: Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013-2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified: <70 years (SGLT2i n=66,810, DPP4i n=76,172), ≥70 years (SGLT2i n=10,419, DPP4i n=33,434). Outcomes were assessed using the instrumental variable causal inference method and prescriber preference as the instrument. RESULTS: Risk of diabetic ketoacidosis was increased with SGLT2i in those aged ≥70 (incidence rate ratio compared with DPP4i: 3.82 [95% CI 1.12, 13.03]), but not in those aged <70 (1.12 [0.41, 3.04]). However, incidence rates with SGLT2i in those ≥70 was low (29.6 [29.5, 29.7]) per 10,000 person-years. SGLT2i were associated with similarly increased risk of genital infection in both age groups (incidence rate ratio in those <70: 2.27 [2.03, 2.53]; ≥70: 2.16 [1.77, 2.63]). There was no evidence of an increased risk of volume depletion, poor micturition control, urinary frequency, falls or amputation with SGLT2i in either age group. In those ≥70, HbA1c reduction was similar between SGLT2i and DPP4i (-0.3 mmol/mol [-1.6, 1.1], -0.02% [0.1, 0.1]), but in those <70, SGLT2i were more effective (-4 mmol/mol [4.8, -3.1], -0.4% [-0.4, -0.3]). CONCLUSIONS/INTERPRETATION: Causal analysis suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes.
引用
- Güdemann LM, Young KG, Thomas NJM, et al. Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. 2024. PMID: 38836934. doi:10.1007/s00125-024-06190-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。